Developer docs
API playgroundTry for free, no card

Search company profiles

Flightpath Biosciences

Full company profile

uuid00027y8

Namestring
Flightpath Biosciences
Legal namestring
Flightpath Biosciences, Inc.
Websiteurl
flightpath.bio
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Flightpath Biosciences is a clinical-stage biotechnology company headquartered in Detroit, Michigan (with a Berkeley, California office) that develops precision antibiotics through its proprietary Targeted Bacterial Deletion™ platform. The platform is designed to selectively remove pathogenic gram-negative bacteria that drive inflammation, immune dysregulation, and tissue damage in infection-driven complex diseases, while preserving the healthy microbiome. The company targets a deliberately broad set of indications where specific gram-negative organisms are causally implicated: Lyme disease and post-treatment Lyme disease (Borrelia burgdorferi), colorectal cancer (Fusobacterium nucleatum), inflammatory bowel disease (adherent-invasive E. coli), periodontal disease (P. gingivalis and other keystone pathogens), bacterial vaginosis and endometriosis (Gardnerella vaginalis, Fusobacterium), and complicated urinary tract infections and sepsis (resistant E. coli, Klebsiella pneumoniae, Enterobacter cloacae). Its clinical-stage pipeline comprises FP530 (Forazemin), an orally bioavailable peptide deformylase inhibitor licensed from Northeastern University that is now the lead candidate; FP385 (lolevexin), a gut-restricted LolCDE inhibitor licensed from the University of Illinois; FP380, a systemic LolCDE inhibitor targeting AMR-driven cUTI and sepsis; and the previously prioritized FP-100 (hygromycin A), which was deprioritized in May 2026 due to insufficient oral bioavailability in human studies.

The underlying technology is sourced exclusively through academic licensing agreements rather than internally originated discovery: FP530 and FP-100 from Northeastern University's Antimicrobial Drug Discovery Center (led by scientific cofounder Kim Lewis, PhD), and FP385/FP380/lolamicin from the University of Illinois Urbana-Champaign. A co-development agreement with the Forsyth Institute extends FP-100's application into oral disease, and a prior Illumina Accelerator affiliation generated what the company describes as the largest clinical biomarker study in Chronic Lyme Disease.

Commercially, Flightpath is pre-revenue with no product sales, no licensing income, and no disclosed pricing. Its stated revenue model is future pharmaceutical commercialization, expected to be executed through partnerships with larger pharmaceutical companies for global distribution and commercialization rights following FDA approval. The company raised approximately $8 million in a Series A round closing in 2024 (with related SEC Form D activity), supported by Ann Arbor SPARK, the Michigan Innovation and Commercialization Fund, and disease-focused foundations including The Steven & Alexandra Cohen Foundation, Bay Area Lyme Foundation, and Global Lyme Alliance. With 1–10 employees and most assets at preclinical-to-Phase I stage, the company is best characterized as an early-stage clinical venture whose value will be determined by Phase II/III outcomes and partnership economics rather than near-term product revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDetroit, United States
HQ citystring
Detroit
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
narrow-spectrum antibiotics, microbiome-sparing therapeutics, gram-negative antibiotics, infectious disease drug development, biopharmaceutical pipeline
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing drug candidates through clinical trials with plans for FDA approval and commercialization. Revenue will be generated through product sales following regulatory approval.

flightpath.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Targeted Bacterial Deletion™
Description

Proprietary platform technology designed to address infection-driven complex disease by selectively removing harmful gram-negative bacteria without negatively impacting the surrounding microbiome.

flightpath.bio
Core offering1 text field

Flightpath Biosciences is a clinical-stage biopharmaceutical company developing narrow-spectrum, microbiome-sparing antibiotic drug candidates through its proprietary Targeted Bacterial Deletion™ platform. The company licenses proprietary drug compounds from Northeastern University and the University of Illinois, advancing them through clinical trials to treat infection-driven complex diseases including Lyme disease, colorectal cancer, inflammatory bowel disease, periodontal disease, complicated UTIs, bacterial vaginosis, and endometriosis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • FP-100 cleared B. burgdorferi infection in mice and was less disruptive to fecal microbiome than clinically relevant antibiotics
+3 more records
Product overview1 text field

Flightpath Biosciences is a clinical-stage biotechnology company pioneering a Targeted Bacterial Deletion™ platform for treating infection-driven complex diseases. The company is developing multiple targeted drug candidates: FP530 (Forazemin) as the current lead clinical-stage compound (peptide deformylase inhibitor for Lyme disease, periodontal disease, and reproductive tract diseases); FP385 (lolevexin, gut-restricted LolCDE inhibitor for IBD and colorectal cancer); FP380 (systemic LolCDE inhibitor for complicated UTI and sepsis); and previously developed FP-100 (hygromycin A) for Lyme disease before strategic refocusing due to bioavailability limitations. These precision therapeutics aim to eliminate pathogenic gram-negative bacteria while sparing the healthy microbiome.

Product and service4 records
1FP530 (Forazemin)
CategoryMicrobiome-sparing antibiotic drug candidate
Description

A clinical-stage, orally bioavailable small molecule peptide deformylase inhibitor that selectively targets gram-negative bacteria including Fusobacterium nucleatum, Porphyromonas gingivalis, Treponema, Borrelia burgdorferi, Gardnerella vaginalis, and Helicobacter pylori, while preserving the healthy microbiome. Designed to eradicate gram-negative bacteria from the oral cavity, GI tract, and reproductive system for indications including Lyme disease, periodontal disease, bacterial vaginosis, and endometriosis.

2FP385 (lolevexin)
CategoryMicrobiome-sparing antibiotic drug candidate
Description

A gut-restricted small molecule LolCDE inhibitor targeting Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae without disrupting healthy gut bacteria. Developed for AIEC-positive IBD and complicated colorectal cancers with intractable Klebsiella pneumoniae and/or E. coli infections.

3FP380
CategoryMicrobiome-sparing antibiotic drug candidate
Description

A systemic small molecule LolCDE inhibitor targeting Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae without disrupting healthy gut bacteria. Designed to address causal bacteria in complicated UTI and sepsis cases unresponsive to current medications due to antimicrobial resistance.

4FP-100 (Hygromycin A)
CategoryMicrobiome-sparing antibiotic drug candidate
Description

An orally available, narrow-spectrum bactericidal compound with selective activity against Borrelia burgdorferi (Lyme disease), Treponemes (syphilis and gum disease), and Fusobacterium nucleatum (implicated in colorectal cancer and women's health issues). Licensed from Northeastern University; Phase I human dosing began in May 2024 before being deprioritized due to limited oral bioavailability in humans.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-03
Description

Multi-indication and multi-year co-development agreement to develop new products and intellectual property beginning with Flightpath's orally bioavailable, narrow-spectrum antibiotic FP-100 for prevention and treatment of oral diseases. Leverages Forsyth's intellectual property, animal models, and clinical expertise in oral health.

Strategic tierCoreTypeTechnology or Integration
Description

Flightpath licenses FP530 (Forazemin), a peptide deformylase inhibitor rediscovered by co-founder Kim Lewis, PhD, from Northeastern University's Antimicrobial Drug Discovery Center. This is the second license from Northeastern for Flightpath, following the earlier FP-100 license. Dr. Lewis serves as Head of Northeastern's Antimicrobial Drug Discovery Center.

Strategic tierCoreTypeTechnology or Integration
Description

Flightpath licenses lolamicin, a selective, microbiome-sparing drug platform technology developed at the University of Illinois Urbana-Champaign. This platform technology targets the lipoprotein transport system in Gram-negative bacteria.

Strategic tierSupportingTypeOthers
Description

Flightpath Biosciences graduated from the Illumina Accelerator program and completed the largest and most comprehensive clinical biomarker study in Chronic Lyme Disease.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public clinical-stage developer of oral antibiotics targeting drug-resistant gram-negative infections, including complicated UTIs — the exact indication pursued by Flightpath's FP380 systemic LolCDE inhibitor. Overlapping mechanism class (novel small-molecule antibiotics) and identical patient population make Iterum the closest comparable peer.

TypeDirect peer
Description

Clinical-stage antibiotic developer focused on novel mechanisms for MDR gram-negative infections (pulmonary, cUTI). Shares the same development model (clinical-stage biotech, single-target programs against resistant bacteria, reliance on pharma partnerships) and competes for the same hospital-based antimicrobial market as Flightpath's FP380.

TypeDirect peer
Description

Acquired by Innoviva in 2022; develops precision antibiotics for serious gram-negative infections, including lead programs targeting Enterobacterales and Pseudomonas. Direct mechanism overlap with Flightpath's gram-negative LolCDE inhibitors (FP385, FP380), targeting identical bacterial pathogens (E. coli, Klebsiella, Enterobacter).

TypeBroad incumbent
Description

Developed and commercialized omadacycline (Nuzyra), a broad-spectrum antibiotic approved for community-acquired pneumonia and skin infections. As a larger antibiotic player with regulatory and commercial infrastructure, serves as a comparable model for the commercial path Flightpath would need to traverse post-approval.

TypeBroad incumbent
Description

Established antibiotic developer with approved products (delafloxacin, oritavancin) targeting resistant gram-positive and gram-negative infections. Comparable commercial-stage antimicrobial business model and provides a reference point for what a scaled antibiotic company looks like once Flightpath's candidates reach approval.

6Nabriva Therapeutics
TypeEmerging player
Description

Small-cap developer of antibiotics for resistant community-acquired infections (lefamulin, CONTEPO). Comparable clinical-stage antibiotic business with similar go-to-market challenges and small operating footprint, providing a meaningful but partial overlap with Flightpath's commercial trajectory.

TypeEmerging player
Description

Pioneer in microbiome therapeutics (VOWST was the first FDA-approved oral microbiome therapeutic). Competes with Flightpath in the bacterial-driven disease space but from the opposite direction — adding beneficial consortia rather than selectively removing pathogens. Comparable clinical-stage biotech focused on microbiome-linked indications including IBD.

TypeEmerging player
Description

Clinical-stage developer of defined bacterial consortia designed to modulate the gut microbiome for CDI, IBD, and food allergy. Operates in the same 'microbiome-targeting for complex disease' strategic space as Flightpath but with a different mechanism, making it a meaningful but partial comparator.

TypeEmerging player
Description

Develops engineered bacteriophage therapies that selectively kill specific pathogens (E. coli in UTI, S. aureus in chronic rhinosinusitis). Shares Flightpath's 'targeted bacterial deletion' strategic paradigm — precision removal of specific pathogens while sparing microbiota — though via phage rather than small molecules, making it a strong conceptual peer.

TypeOthers
Description

Euronext-listed developer of microbiome-based therapeutics for oncology, GvHD, and infectious disease. Operates from a microbiome-modulation paradigm in indications that overlap partially with Flightpath's bacterial-driven disease targets, including oncology-supportive care where microbiome composition affects patient outcomes.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flightpath Biosciences

Infectious Disease Therapeuticsflightpath.bio

What Flightpath Biosciences does

Flightpath Biosciences is a clinical-stage biotechnology company headquartered in Detroit, Michigan (with a Berkeley, California office) that develops precision antibiotics through its proprietary Targeted Bacterial Deletion™ platform. The platform is designed to selectively remove pathogenic gram-negative bacteria that drive inflammation, immune dysregulation, and tissue damage in infection-driven complex diseases, while preserving the healthy microbiome. The company targets a deliberately broad set of indications where specific gram-negative organisms are causally implicated: Lyme disease and post-treatment Lyme disease (Borrelia burgdorferi), colorectal cancer (Fusobacterium nucleatum), inflammatory bowel disease (adherent-invasive E. coli), periodontal disease (P. gingivalis and other keystone pathogens), bacterial vaginosis and endometriosis (Gardnerella vaginalis, Fusobacterium), and complicated urinary tract infections and sepsis (resistant E. coli, Klebsiella pneumoniae, Enterobacter cloacae). Its clinical-stage pipeline comprises FP530 (Forazemin), an orally bioavailable peptide deformylase inhibitor licensed from Northeastern University that is now the lead candidate; FP385 (lolevexin), a gut-restricted LolCDE inhibitor licensed from the University of Illinois; FP380, a systemic LolCDE inhibitor targeting AMR-driven cUTI and sepsis; and the previously prioritized FP-100 (hygromycin A), which was deprioritized in May 2026 due to insufficient oral bioavailability in human studies.

The underlying technology is sourced exclusively through academic licensing agreements rather than internally originated discovery: FP530 and FP-100 from Northeastern University's Antimicrobial Drug Discovery Center (led by scientific cofounder Kim Lewis, PhD), and FP385/FP380/lolamicin from the University of Illinois Urbana-Champaign. A co-development agreement with the Forsyth Institute extends FP-100's application into oral disease, and a prior Illumina Accelerator affiliation generated what the company describes as the largest clinical biomarker study in Chronic Lyme Disease.

Commercially, Flightpath is pre-revenue with no product sales, no licensing income, and no disclosed pricing. Its stated revenue model is future pharmaceutical commercialization, expected to be executed through partnerships with larger pharmaceutical companies for global distribution and commercialization rights following FDA approval. The company raised approximately $8 million in a Series A round closing in 2024 (with related SEC Form D activity), supported by Ann Arbor SPARK, the Michigan Innovation and Commercialization Fund, and disease-focused foundations including The Steven & Alexandra Cohen Foundation, Bay Area Lyme Foundation, and Global Lyme Alliance. With 1–10 employees and most assets at preclinical-to-Phase I stage, the company is best characterized as an early-stage clinical venture whose value will be determined by Phase II/III outcomes and partnership economics rather than near-term product revenue.

Flightpath Biosciences firmographics

Firmographics
Name
Flightpath Biosciences
Legal name
Flightpath Biosciences, Inc.
Website
https://flightpath.bio
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Where Flightpath Biosciences is headquartered

Location

Headquarters

HQ city
Detroit
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Flightpath Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing drug candidates through clinical trials with plans for FDA approval and commercialization. Revenue will be generated through product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Flightpath Biosciences product offering

Product offering

Core offering

Flightpath Biosciences is a clinical-stage biopharmaceutical company developing narrow-spectrum, microbiome-sparing antibiotic drug candidates through its proprietary Targeted Bacterial Deletion™ platform. The company licenses proprietary drug compounds from Northeastern University and the University of Illinois, advancing them through clinical trials to treat infection-driven complex diseases including Lyme disease, colorectal cancer, inflammatory bowel disease, periodontal disease, complicated UTIs, bacterial vaginosis, and endometriosis.

Product overview

Flightpath Biosciences is a clinical-stage biotechnology company pioneering a Targeted Bacterial Deletion™ platform for treating infection-driven complex diseases. The company is developing multiple targeted drug candidates: FP530 (Forazemin) as the current lead clinical-stage compound (peptide deformylase inhibitor for Lyme disease, periodontal disease, and reproductive tract diseases); FP385 (lolevexin, gut-restricted LolCDE inhibitor for IBD and colorectal cancer); FP380 (systemic LolCDE inhibitor for complicated UTI and sepsis); and previously developed FP-100 (hygromycin A) for Lyme disease before strategic refocusing due to bioavailability limitations. These precision therapeutics aim to eliminate pathogenic gram-negative bacteria while sparing the healthy microbiome.

Differentiator

Problem solved

Functional benefit

Brands

  • Targeted Bacterial Deletion™: Proprietary platform technology designed to address infection-driven complex disease by selectively removing harmful gram-negative bacteria without negatively impacting the surrounding microbiome.

Products and services

  • FP530 (Forazemin) A clinical-stage, orally bioavailable small molecule peptide deformylase inhibitor that selectively targets gram-negative bacteria including Fusobacterium nucleatum, Porphyromonas gingivalis, Treponema, Borrelia burgdorferi, Gardnerella vaginalis, and Helicobacter pylori, while preserving the healthy microbiome. Designed to eradicate gram-negative bacteria from the oral cavity, GI tract, and reproductive system for indications including Lyme disease, periodontal disease, bacterial vaginosis, and endometriosis.
  • FP385 (lolevexin) A gut-restricted small molecule LolCDE inhibitor targeting Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae without disrupting healthy gut bacteria. Developed for AIEC-positive IBD and complicated colorectal cancers with intractable Klebsiella pneumoniae and/or E. coli infections.
  • FP380 A systemic small molecule LolCDE inhibitor targeting Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae without disrupting healthy gut bacteria. Designed to address causal bacteria in complicated UTI and sepsis cases unresponsive to current medications due to antimicrobial resistance.
  • FP-100 (Hygromycin A) An orally available, narrow-spectrum bactericidal compound with selective activity against Borrelia burgdorferi (Lyme disease), Treponemes (syphilis and gum disease), and Fusobacterium nucleatum (implicated in colorectal cancer and women's health issues). Licensed from Northeastern University; Phase I human dosing began in May 2024 before being deprioritized due to limited oral bioavailability in humans.

Quantifiable outcome

  • FP-100 cleared B. burgdorferi infection in mice and was less disruptive to fecal microbiome than clinically relevant antibiotics
  • +3 more outcomes

Companies that use Flightpath Biosciences

Customer profile

Segments6 records

Ideal customer profiles2 records

Flightpath Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Flightpath Biosciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Forsyth InstitutecoreStrategic or Co-development Partner · 3 October 2023Multi-indication and multi-year co-development agreement to develop new products and intellectual property beginning with Flightpath's orally bioavailable, narrow-spectrum antibiotic FP-100 for prevention and treatment of oral diseases. Leverages Forsyth's intellectual property, animal models, and clinical expertise in oral health.
  • Northeastern UniversitycoreTechnology or IntegrationFlightpath licenses FP530 (Forazemin), a peptide deformylase inhibitor rediscovered by co-founder Kim Lewis, PhD, from Northeastern University's Antimicrobial Drug Discovery Center. This is the second license from Northeastern for Flightpath, following the earlier FP-100 license. Dr. Lewis serves as Head of Northeastern's Antimicrobial Drug Discovery Center.
  • University of IllinoiscoreTechnology or IntegrationFlightpath licenses lolamicin, a selective, microbiome-sparing drug platform technology developed at the University of Illinois Urbana-Champaign. This platform technology targets the lipoprotein transport system in Gram-negative bacteria.
  • Illumina AcceleratorsupportingOthersFlightpath Biosciences graduated from the Illumina Accelerator program and completed the largest and most comprehensive clinical biomarker study in Chronic Lyme Disease.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Flightpath Biosciences competitors and assessment

Company assessment

Direct peers

  • Iterum Therapeutics: Public clinical-stage developer of oral antibiotics targeting drug-resistant gram-negative infections, including complicated UTIs — the exact indication pursued by Flightpath's FP380 systemic LolCDE inhibitor. Overlapping mechanism class (novel small-molecule antibiotics) and identical patient population make Iterum the closest comparable peer.
  • Spero Therapeutics: Clinical-stage antibiotic developer focused on novel mechanisms for MDR gram-negative infections (pulmonary, cUTI). Shares the same development model (clinical-stage biotech, single-target programs against resistant bacteria, reliance on pharma partnerships) and competes for the same hospital-based antimicrobial market as Flightpath's FP380.
  • Entasis Therapeutics (an Innoviva company): Acquired by Innoviva in 2022; develops precision antibiotics for serious gram-negative infections, including lead programs targeting Enterobacterales and Pseudomonas. Direct mechanism overlap with Flightpath's gram-negative LolCDE inhibitors (FP385, FP380), targeting identical bacterial pathogens (E. coli, Klebsiella, Enterobacter).

Broad incumbents

  • Paratek Pharmaceuticals (now Paratek / nonprofit): Developed and commercialized omadacycline (Nuzyra), a broad-spectrum antibiotic approved for community-acquired pneumonia and skin infections. As a larger antibiotic player with regulatory and commercial infrastructure, serves as a comparable model for the commercial path Flightpath would need to traverse post-approval.
  • Melinta Therapeutics: Established antibiotic developer with approved products (delafloxacin, oritavancin) targeting resistant gram-positive and gram-negative infections. Comparable commercial-stage antimicrobial business model and provides a reference point for what a scaled antibiotic company looks like once Flightpath's candidates reach approval.

Emerging players

  • Nabriva Therapeutics: Small-cap developer of antibiotics for resistant community-acquired infections (lefamulin, CONTEPO). Comparable clinical-stage antibiotic business with similar go-to-market challenges and small operating footprint, providing a meaningful but partial overlap with Flightpath's commercial trajectory.
  • Seres Therapeutics: Pioneer in microbiome therapeutics (VOWST was the first FDA-approved oral microbiome therapeutic). Competes with Flightpath in the bacterial-driven disease space but from the opposite direction — adding beneficial consortia rather than selectively removing pathogens. Comparable clinical-stage biotech focused on microbiome-linked indications including IBD.
  • Vedanta Biosciences: Clinical-stage developer of defined bacterial consortia designed to modulate the gut microbiome for CDI, IBD, and food allergy. Operates in the same 'microbiome-targeting for complex disease' strategic space as Flightpath but with a different mechanism, making it a meaningful but partial comparator.
  • Locus Biosciences: Develops engineered bacteriophage therapies that selectively kill specific pathogens (E. coli in UTI, S. aureus in chronic rhinosinusitis). Shares Flightpath's 'targeted bacterial deletion' strategic paradigm — precision removal of specific pathogens while sparing microbiota — though via phage rather than small molecules, making it a strong conceptual peer.

Others

  • MaaT Pharma: Euronext-listed developer of microbiome-based therapeutics for oncology, GvHD, and infectious disease. Operates from a microbiome-modulation paradigm in indications that overlap partially with Flightpath's bacterial-driven disease targets, including oncology-supportive care where microbiome composition affects patient outcomes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

Flightpath Biosciences social profiles

Digital presence

Flightpath Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flightpath Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Flightpath Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flightpath Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flightpath Biosciences

What does Flightpath Biosciences do?

Flightpath Biosciences is a clinical-stage biopharmaceutical company developing narrow-spectrum, microbiome-sparing antibiotic drug candidates through its proprietary Targeted Bacterial Deletion™ platform. The company licenses proprietary drug compounds from Northeastern University and the University of Illinois, advancing them through clinical trials to treat infection-driven complex diseases including Lyme disease, colorectal cancer, inflammatory bowel disease, periodontal disease, complicated UTIs, bacterial vaginosis, and endometriosis.

Is Flightpath Biosciences a public or private company?

Flightpath Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Flightpath Biosciences founded?

Flightpath Biosciences was founded in 2019. It employs 1 to 10 people.

Where is Flightpath Biosciences based?

Flightpath Biosciences is headquartered in Detroit, United States, in the North America region.

How does Flightpath Biosciences make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Flightpath Biosciences's main competitors?

Direct peers on record are Iterum Therapeutics, Spero Therapeutics and Entasis Therapeutics (an Innoviva company). Broad incumbents are Paratek Pharmaceuticals (now Paratek / nonprofit) and Melinta Therapeutics. Emerging players are Nabriva Therapeutics, Seres Therapeutics, Vedanta Biosciences and Locus Biosciences. MaaT Pharma is listed as an others.

Does Flightpath Biosciences have an API?

No public API is recorded for Flightpath Biosciences.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals